ASH 2019 | Novel CD19t T-APCs enhance CD19 CAR T-cell persistance
Colleen Annesley
• 7 Dec 2019
Colleen Annesley, MD, Seattle Children’s Research Institute, Seattle, WA, outlines the PLAT-03 clinical trial (NCT03186118). This study explored the hypothesis that episodic antigen exposure using CD19t T-cell antigen presenting cells (T-APCs) could initiate CD19 CAR T-cell proliferation and re-activation in vivo, resulting in more durable CAR T-cell persistence and a reduced risk of CD19+ relapse. Results suggest CD19t T-APCs have the potential to enhance durable CD19 CAR T-cell persistence. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
